A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
Description: 
To estimate the objective response rate of patients with metastatic colorectal cancer treated with pembrolizumab and cetuximab. To estimate the 6-month progression-free survival (PFS) rate of patients with metastatic colorectal cancer treated with pembrolizumab and cetuximab. To examine the adverse event profile of combining pembrolizumab and cetuximab.
Study Number: 

I 274515

Phase: 
Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02713373

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.